L-Dopa: how it may axacerbate parkinsonian symptoms

Abstract

To maintain a stable the therapeutic effect on mobility the day is a great problem with oral L- dopa treatment in Parkinson's disease. A reviewof the literature shows, that although a multiplicity of separate factors influences this therapy, the cause of fluctuations in motor performance after L- dopa in parkinsonian patients is nuclear. Gudrun H.M. Paalzow and Lennart K. Paalzow suggest that in certain circumstances, the drug itself may enhance parkinson symptoms. They describe how pharmacokinetic factors may precipitate time-dependent oscillations in motor function after oral L- dopa administration.